利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.035 秒)

    Oxytocin receptor agonists for the treatment of CNS diseases
    9.
    发明申请
    Oxytocin receptor agonists for the treatment of CNS diseases 有权
    催产素受体激动剂用于治疗CNS疾病

    公开(公告)号：US20150322058A1

    公开(公告)日：2015-11-12

    申请号：US14802469

    申请日：2015-07-17

    申请人： HOFFMANN-LA ROCHE INC.

    发明人： Caterina Bissantz ,  Christophe Grundschober ,  Matthias Nettekoven ,  Jean-Marc Plancher ,  Walter Vifian

    IPC分类号： C07D417/04 ,  C07D231/42 ,  C07D403/04 ,  C07D401/04

    CPC分类号： C07D417/04 ,  A61K31/415 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  C07D231/42 ,  C07D401/04 ,  C07D403/04

    摘要： The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.

    摘要翻译： 本发明涉及式I化合物的用途，其中A1是苯基或含有1,2或3个选自N或S的杂原子的五或六元的二芳基; R1是氢，低级烷基，卤素，被卤素或环烷基取代的低级烷基; A2是苯基; R 2为卤素，低级烷基，被卤素取代的低级烷基，被卤素取代的低级烷氧基，氰基，被卤素取代的S-低级烷基，被卤素取代的S（O）2 - 低级烷基） n为1或2; 或药学上可接受的酸加成盐或外消旋混合物或其相应的对映异构体和/或光学异构体，用于治疗自闭症，压力，包括创伤后应激障碍，焦虑，包括焦虑症和抑郁症，精神分裂症，精神疾病和 记忆丧失，酒精戒断，药物成瘾和治疗Prader-Willi综合征。